valuating Therapy Results and Analysis of Immediate and Long-term Treatment Toxicity in a Clinical Case Series of Nasopharyngeal Carcinoma

Carmen Salvador Coloma, Miguel Pastor Borgoñón, Koen Jerusalem, Óscar Mauricio Niño Gómez, Encarnación Reche Santos, Joaquín Montalar Salcedo


Introduction and objective:
Nasopharyngeal carcinomas differ from other head and neck tumors. Patients have a higher rate of survival and thereby have a higher chance of presenting late toxicity, affecting their quality of life. We have tried to evaluate the most relevant late toxicities.

Material and methods:
We conducted a retrospective analysis in a series of 58 patients diagnosed with nasopharyngeal carcinoma between 1987 and 2014. The non-epithelial histological types were excluded from the study. We analyzed late toxicity and survival using SPSS version 19.

We included 58 patients, 93,1% of whom presented locally advanced disease at the time of diagnosis. The predominant subtype was found to be undifferentiated carcinoma. The treatment response rate was 91,2% (75,4% complete response and 15,8% partial response). The relapse rate was 35,1% (35% local relapse and 65% systemic relapse). The median disease-free survival was 150 months and the mean global survival was 224 months (168-279).

Nasopharyngeal carcinoma is usually diagnosed in a locally advanced stage. Treatment is based on the use of chemotherapy and radiotherapy, obtaining a high response rate. Currently, there is large group of survivors, whose quality of life is severely affected by late toxicity.


Nasopharyngeal carcinoma; long-term treatment toxicity; quality of life; chemotherapy; radiotherapy.

Full Text:



Daniel T.T. Chua, Jun Ma, Jonathan S.T. Sham, Hai-Qiang Mai, Damon T.K. Choy, Ming-Huang Hong, Tai-Xiang Lu, and Hua-Qing Min Long-Term Survival After Cisplatin-Based Induction Chemotherapy and Radiotherapy for Nasopharyngeal Carcinoma: A Pooled Data Analysis of Two Phase III Trials. 2005; 23:6. DOI: 10.1200/JCO.2005.12.081

Wei-Hua Jia, Hai-De Qin. Non-viral environmental risk factors for nasopharyngeal carcinoma: A systematic review. Seminars in Cancer Biology 2012; 22: 117– 126

Yuste izquierdo A, Segura Huerta A, Pastor Borgonón, López-Tendero P, Pérez Fidalgo JA, Gironés Sarrió R, Herránz Fernández C. Resultados asistenciales de un único centro en el tratamiento del carcinoma indiferenciado de nasofarínge. Oncología 2002;25 (10): 460-465.

Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006;15:1765–77.

Sham JST, Chay D, Wei WI. Nasopharyngeal carcinoma: orderly neck node spread. Int J Radiat Onco Biol Phys 1990; 19: 929-933.

Curado MP, Edwards B, Shin HR et al. (eds). Cancer Incidence in Five Continents, Vol. IX. IARC Scientific publications 2007: 160.

Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002 Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase. 2004; 5 (version 2.0)

P. Bossi1, E. Orlandi2, C. Bergamini1, L. D. Locati1, R. Granata1, A. Mirabile1, D. Parolini1, M. Franceschini2, C. Fallai2, P. Olmi2, P. Quattrone3, P. Potepan4, A. Gloghini5, R. Miceli6, F. Mattana6, G. Scaramellini7 & L. Licitra Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer. Annals of Oncology 22: 2495–2500, 2011. doi:10.1093/annonc/mdq783. Published online 11 March 2011

American Joint Committee on Cancer (AJCC) staging system for NPC, seventh edition (2010)

A W M Lee, S C K Law, W Foo, Y F Poon, D K K Chan, S K O, S Y Tung, F K Cheung, M Thaw, and J H C Ho. Nasopharyngeal carcinoma: local control by megavoltage irradiation. The British Journal of Radiology 1993 66:786, 528-536

Stephen Wan Leung, Tsair-Fwu Lee, Chih-Yen Chien, Pei-Ju Chao, Wen-Ling Tsai and Fu-Min Fang. Health-related Quality of life in 40 head and neck cancer survivors after radiotherapy using EORTC QLQ-C30 and QLQ-H&N35 questionnaires. Wan Leung et al. BMC Cancer 2011, 11:128.



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

eISSN: 2312-0398

Asia Press is a professional Science, Technology and Medicine publisher, who owns rapid publication, Peer-Reviewed, Open Access Journals. Asia Press aims to promote “knowledge sharing”. As you know, the main barrier for free “knowledge sharing” is the cost of publishing and transfer. In order to encourage scholars and scientists to the max, and devote whole power to realize the aim of “knowledge sharing” and the benefit of “all” mankind, Asia Press performs a permanent policy of no charge for publication and access, and always open its door for authors worldwide.

© 2013-2017 by the Asia Press. All rights reserved.